Evolva Holding SA (ELVAF)
USD 0.9
(0.0%)
USD 0.9
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -92.24 Million CHF | 101.25% |
| 2022 | -40.39 Million CHF | 3.9% |
| 2021 | -42.02 Million CHF | -68.76% |
| 2020 | -24.9 Million CHF | -23.73% |
| 2019 | -20.12 Million CHF | 34.26% |
| 2018 | -30.61 Million CHF | 30.22% |
| 2017 | -43.88 Million CHF | -4.48% |
| 2016 | -41.99 Million CHF | -17.55% |
| 2015 | -35.72 Million CHF | -56.99% |
| 2014 | -22.75 Million CHF | -28.66% |
| 2013 | -17.68 Million CHF | 11.43% |
| 2012 | -19.96 Million CHF | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -9.81 Million CHF | -100.0% |
| 2023 Q4 | 39.05 Million CHF | 656.93% |
| 2023 Q3 | 5.16 Million CHF | 152.58% |
| 2023 FY | 506.2 Thousand CHF | 101.25% |
| 2023 Q1 | -4.9 Million CHF | 48.14% |
| 2022 FY | -40.39 Million CHF | 3.9% |
| 2022 Q3 | -4.71 Million CHF | 66.08% |
| 2022 Q4 | -9.46 Million CHF | -100.68% |
| 2022 Q2 | -13.89 Million CHF | -125.17% |
| 2022 Q1 | -6.17 Million CHF | 58.96% |
| 2021 Q1 | -8.68 Million CHF | 29.39% |
| 2021 Q2 | -17.36 Million CHF | -100.0% |
| 2021 FY | -42.02 Million CHF | -68.76% |
| 2021 Q3 | -7.51 Million CHF | 56.69% |
| 2021 Q4 | -15.03 Million CHF | -100.0% |
| 2020 Q2 | -12.61 Million CHF | -100.0% |
| 2020 Q4 | -12.29 Million CHF | -100.0% |
| 2020 Q1 | -6.3 Million CHF | 40.25% |
| 2020 Q3 | -6.14 Million CHF | 51.26% |
| 2020 FY | -24.9 Million CHF | -23.73% |
| 2019 Q4 | -10.55 Million CHF | -100.0% |
| 2019 Q3 | -5.27 Million CHF | 44.89% |
| 2019 Q2 | -9.57 Million CHF | -100.0% |
| 2019 Q1 | -4.78 Million CHF | 36.05% |
| 2019 FY | -20.12 Million CHF | 34.26% |
| 2018 Q2 | -7.88 Million CHF | 0.0% |
| 2018 Q3 | -7.48 Million CHF | 5.03% |
| 2018 FY | -30.61 Million CHF | 30.22% |
| 2018 Q4 | -7.48 Million CHF | 0.0% |
| 2018 Q1 | -7.88 Million CHF | 34.91% |
| 2017 Q3 | -12.1 Million CHF | -17.1% |
| 2017 Q4 | -12.1 Million CHF | 0.0% |
| 2017 FY | -43.88 Million CHF | -4.48% |
| 2017 Q2 | -10.34 Million CHF | 0.0% |
| 2017 Q1 | -10.34 Million CHF | -0.39% |
| 2016 Q3 | -10.3 Million CHF | -0.16% |
| 2016 FY | -41.99 Million CHF | -17.55% |
| 2016 Q1 | -10.28 Million CHF | -9.5% |
| 2016 Q2 | -10.28 Million CHF | 0.0% |
| 2016 Q4 | -10.3 Million CHF | 0.0% |
| 2015 Q1 | -8.47 Million CHF | -42.19% |
| 2015 Q4 | -9.39 Million CHF | 0.0% |
| 2015 Q3 | -9.39 Million CHF | -10.86% |
| 2015 FY | -35.72 Million CHF | -56.99% |
| 2015 Q2 | -8.47 Million CHF | 0.0% |
| 2014 FY | -22.75 Million CHF | -28.66% |
| 2014 Q3 | -5.95 Million CHF | -9.92% |
| 2014 Q1 | -5.42 Million CHF | -24.69% |
| 2014 Q2 | -5.42 Million CHF | 0.0% |
| 2014 Q4 | -5.95 Million CHF | 0.0% |
| 2013 Q4 | -4.34 Million CHF | 0.0% |
| 2013 FY | -17.68 Million CHF | 11.43% |
| 2013 Q1 | -4.49 Million CHF | -1.14% |
| 2013 Q2 | -4.49 Million CHF | 0.0% |
| 2013 Q3 | -4.34 Million CHF | 3.33% |
| 2012 Q4 | -4.44 Million CHF | 0.0% |
| 2012 Q3 | -4.44 Million CHF | 0.0% |
| 2012 FY | -19.96 Million CHF | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -6479.593% |
| CSL Limited | 3.7 Billion USD | 102.492% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -28.5% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 1976.884% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -35144.989% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -416.867% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 212.698% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -5905.362% |
| Mesoblast Limited | -84.14 Million USD | -9.624% |
| Marizyme, Inc. | -34.08 Million USD | -170.621% |
| Genus plc | 6.4 Million USD | 1541.333% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 1046.838% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -9804.153% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -1004.734% |
| ContraFect Corporation | -56.88 Million USD | -62.15% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -1925.266% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -38.67 Million USD | -138.536% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -3253.351% |
| MultiCell Technologies, Inc. | -722.81 USD | -12761939.817% |
| Accustem Sciences Inc. | -3.74 Million USD | -2362.226% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -56.374% |
| EV Biologics, Inc. | -483.06 Thousand USD | -18995.955% |
| Q BioMed Inc. | -3.44 Million USD | -2577.179% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 2705.799% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -3410.734% |
| Biomind Labs Inc. | -1 Million USD | -9036.789% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -1287.562% |
| Skye Bioscience, Inc. | -13.67 Million USD | -574.712% |
| SQZ Biotechnologies Company | -75.82 Million USD | -21.656% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -307877.097% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -1728.637% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -3136.102% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -481.265% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -23578.748% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -1790.449% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -4543.658% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -4673.094% |
| GB Sciences, Inc. | -1.42 Million USD | -6393.82% |
| Alpha Cognition Inc. | -9.7 Million USD | -850.434% |
| argenx SE | -425.04 Million USD | 78.298% |
| HST Global, Inc. | -140.9 Thousand USD | -65365.378% |
| Halberd Corporation | -75.05 Thousand USD | -122811.792% |
| Enzolytics Inc. | -2.14 Million USD | -4192.875% |
| Resverlogix Corp. | -12.74 Million USD | -623.549% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -2811.532% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -66.184% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -67.803% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -8735.757% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -3079.502% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -3059.687% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -4847.8% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -5740.694% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -2609.13% |
| AVAX Technologies, Inc. | 6.69 Million USD | 1478.26% |
| ONE Bio Corp. | 13.68 Million USD | 774.231% |
| Zenith Capital Corp. | -8.94 Million USD | -931.48% |
| Genscript Biotech Corporation | -415.79 Million USD | 77.815% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -529406.343% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -3656.961% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -53684.355% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -4501.321% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -8100.267% |
| Agentix Corp. | -1.37 Million USD | -6624.614% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.04 Million USD | -2934.135% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -9274.017% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -7244.371% |
| BioStem Technologies, Inc. | -7.77 Million USD | -1085.829% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -50728.057% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -6807.53% |
| LadRx Corporation | -3.82 Million USD | -2312.508% |
| Cell Source, Inc. | -4.32 Million USD | -2032.669% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -22102.157% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -13328.241% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -13328.241% |
| NovAccess Global Inc. | -2.46 Million USD | -3639.533% |
| Affymax, Inc. | -15.04 Million USD | -513.089% |
| Itoco Inc. | -919.14 Thousand USD | -9936.045% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -2076.411% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -8143.548% |
| CytoDyn Inc. | -18.05 Million USD | -410.828% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -366389.074% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -41814.821% |
| Qrons Inc. | -643.67 Thousand USD | -14230.992% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -16234.61% |
| SYBLEU INC | -149.18 Thousand USD | -61734.897% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -4036.785% |
| Rebus Holdings, Inc. | -664 Thousand USD | -13792.364% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -4978.692% |
| Mobile Lads Corp. | -554.55 Thousand USD | -16534.262% |
| International Stem Cell Corporation | -663 Thousand USD | -13813.318% |
| Bioxytran, Inc. | -3.82 Million USD | -2314.706% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -175138.032% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -453416.716% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -154.358% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -5601.193% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -12436.139% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -2865.133% |
| Neutra Corp. | -229.48 Thousand USD | -40096.483% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -425.944% |
| PureTech Health plc | -146.19 Million USD | 36.904% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -329.225% |
| IXICO plc | -1.43 Million USD | -6319.297% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -871.924% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 24.269% |
| CSL Limited | 3.81 Billion USD | 102.42% |
| Cellectis S.A. | -108.85 Million USD | 15.26% |